News

November 11, 2011

Elixir Medical Announces DESolve Nx International Pivotal Trial Initiation for Fully Bioresorbable Coronary Scaffold System

November 9, 2011

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial for DESyne BD™ Novolimus Eluting Coronary Stent with Biodegradable Polymer

November 2, 2011

Elixir Medical Corporation Announces Successful Completion of First-In-Man Study Enrollment for Fully Bioresorbable Drug Eluting Coronary Scaffold System

May 23, 2011

Elixir Medical Receives CE Mark for DESyne™ Novolimus Eluting Coronary Stent System

September 17, 2010

Elixir Medical Corporation Initiates Enrollment in the EXCELLA BD Randomized Clinical Trial of the Elixir Novolimus Eluting Coronary Stent System with Resorbable Polymer

May 26, 2010

Elixir Medical Corporation Announces Excellent Nine Month Safety and Efficacy Results from the EXCELLA II Randomized Clinical Trial

September 22, 2009

Elixir Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorable Polymers during TCT 2009

September 17, 2009

Elixir Medical Announces Activities at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference

October 30, 2008

SurModics Licenses Hydrophilic Coating for Elixir's Drug-Eluting and Bare Metal Stent Delivery Systems

October 16, 2008

Elixir Medical Corporation Announced Positive First-In-Man Results from Three Drug Eluting Coronary Stent Systems

October 10, 2008

Elixir Medical Corporation Licenses Myolimus™ from Novartis Pharma AG for site specific drug delivery applications

October 21, 2007

Elixir Medical Announces Positive Nine-Month Results from the Excella Novolimus-Eluting Coronary Stent System First-In-Man Study

In the News

October 2017

BioWorld MedTech | Vol 21, Issue 200

- Page 7: Elixir shows resolve with DESolve, will push forward in bioresorbable space

June 2015

The MedTech Strategist | Vol 2, Issue 12

- Page 6: Elixir Medical’s Contrarian Play in Cardiology: Go Bioresorbable or Go Home

September 2014

Treatment Strategies Interventional Cardiology | Vol 4, Issue 1

- Page 19: Excella II Randomized Clinical Trial Final 5-Year Results Demonstrate Superior Safety and Efficacy

- Page 38: Live Demonstration of Breakthrough DESolve® 100 by Elixir

- Page 42: Elixir Medical - Full Page Advertisement

June 2013

EP Vantage Interview | Elixir Medical

April 2013

CLINICA | Hot Pick of the Month | Elixir Medical

December 2012

MEDICAL DEVICE DAILY | Elixir looks to future of bioresorbable scaffolds

 

Events

Learn more about Elixir Medical at one of the below events.

Transcatheter Cardiovascular Therapeutics 2017

Oct 29-Nov 2, 2017 – Denver, CO

EuroPCR 2017

May 16-19, 2017 – Paris, France